Back to Peptide Library

GHRP-6

Growth Hormone-Releasing Peptide-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)

Early-Stage ClinicalFDA Category 2Primary Endpoint Met

Access and compounding status raise extra safety and legal questions.

A synthetic peptide that mimics ghrelin (the body's hunger hormone) to stimulate the natural release of growth hormone, which has been shown consistently in small human studies. It has also shown protective effects on various tissues in animal research but has no FDA-approved therapeutic use.

11 studiesUpdated 2026-03-10Intravenous · Subcutaneous · Intraperitoneal · Topical · Intrarenal injection

This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.

Clinical bottom lineMixed evidence

GHRP-6 has moderate clinical evidence but is not FDA-approved.

Access and compounding status raise extra safety and legal questions.

Safety Summary

The side-effect picture is led by appetite stimulation and endocrine spillover rather than serious toxicity. A 12-participant dose-escalation study reported 23 adverse events (6 different event types) with no serious adverse events. Other human summaries reported hunger, heat sensation, nausea, transient facial flushing, and sleepiness. FDA's 503B compounding-risk discussion specifically cites potential cortisol effects and increased blood glucose due to decreased insulin sensitivity. In the 25-person Borges study, no acute changes in IGF-I or glucose were observed in controls PMID 9274702. GHRP-6 is considered the most appetite-stimulating peptide in the GHRP family due to strong ghrelin receptor agonism, distinguishing it from GHRP-2 and ipamorelin. Cortisol and prolactin elevations are generally described as transient PMC5632578. In diabetic rat models, GHRP-6 combined with insulin potentiated weight gain and visceral fat accumulation.

Clinical check-in

If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.

See cited studies on this page (11)

Cited sources

Every claim on this page links to one of the 11 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.

  1. 1PMID 11030292PubMed
  2. 2PMID 9274702PubMed
  3. 3PMID 12809173PubMed
  4. 4PMID 27200188PubMed
  5. 5doi:10.1042/CS20050374DOI
  6. 6doi:10.3389/fphar.2024.1402138DOI
  7. 7PMID 41327290PubMed
  8. 8PMID 41534456PubMed
  9. 9PMID 28469491PubMed
  10. 10PMID 26915318PubMed
  11. 11doi:10.1002/chir.70083DOI